abstract |
Disclosed is a pharmaceutical composition comprising a Btk inhibitor for the treatment of autoimmune disease or disease, heterogeneous immune disease or disease, cancer including lymphoma, and inflammatory disease or disease. The pharmaceutical formulation comprises: (a) about 40 mg to about 200 mg of 1-((R) -3- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] Pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one; (b) about 40 wt% to about 50 wt% diluent; (c) about 3 wt% to about 10 wt% disintegrant. A solid pharmaceutical formulation for oral administration comprising: (d) about 2 wt% to about 7 wt% surfactant; and (e) about 0.2 wt% to about 1.0 wt% lubricant. The dosage form is preferably a hard gelatin capsule. [Selection] Figure 1 |